Prognostic impact of histological subtyping in triple-negative breast cancer

被引:0
|
作者
Grosse, Claudia [1 ]
Noack, Petar [1 ]
Grosse, Alexandra [2 ]
Preuss, Caroline Ines [3 ]
Schwarz, Heike Kathleen [4 ]
Gitter, Thomas [5 ]
Schrenk, Peter [6 ]
Frauchiger-Heuer, Heike [7 ,8 ]
Papassotiropoulos, Barbel [9 ]
Tausch, Christoph [9 ]
Maccio, Umberto [10 ]
Moch, Holger [10 ]
Langer, Rupert [1 ]
Varga, Zsuzsanna [8 ,10 ]
机构
[1] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Pathol & Mol Pathol, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[2] Pathol Inst Enge, Hardturmstr 133, CH-8005 Zurich, Switzerland
[3] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Gynecol Obstet & Gynecol Endocrinol, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[4] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Hematol & Oncol, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[5] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Cent Radiol Inst, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[6] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Gen & Visceral Surg, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[7] Univ Hosp Zurich, Clin Gynecol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland
[8] Univ Hosp Zurich, Comprehens Breast Canc Ctr, Zurich, Switzerland
[9] Breast Ctr Seefeld, Seefeldstr 214, CH-8008 Zurich, Switzerland
[10] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland
关键词
Breast cancer; Triple-negative phenotype; special histological types; Prognostic stratification; Therapy response; CLINICOPATHOLOGICAL FEATURES; METAPLASTIC CARCINOMA; SURVIVAL OUTCOMES; HETEROGENEITY; DISEASE; SUBSET;
D O I
10.1016/j.humpath.2024.105640
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The impact of special histological types (ST) in triple-negative breast cancer (TNBC) and its association with overall outcome has gained increasing relevance as survival has been linked to specific histological TNBC subtypes. We evaluated the clinicopathological and survival data of 598 patients with 613 TNBCs, including 464 TNBCs of no special type (NST) and 149 TNBCs ST (low-grade, n = 12, 8.1%; high-grade, n = 112, 75.2%; apocrine and androgen receptor-positive [APO AR], n = 25, 16.8%). Patients with low-grade TNBC ST and TNBC ST APO AR were significantly older (P G 0.001) and had a lower Ki67 index (P G 0.001) than those with TNBC NST. Patients with high-grade TNBC ST were significantly older (P = 0.006) and had poorer pathological responses to neoadjuvant chemotherapy (NAC) (P G 0.001) than those with TNBC NST. Significant survival differences were observed between low-grade TNBC ST, TNBC ST APO AR, high-grade TNBC ST, and TNBC NST in the entire study group (DFS, P = 0.002; DDFS, P = 0.001) and in the non-NAC subgroup (OS, P = 0.034; DFS, P = 0.001; DDFS, P G 0.001). Patients with low-grade TNBC ST had the best survival outcomes. Patients with highgrade TNBC ST showed significantly worse outcomes than those with TNBC NST (entire study group: OS, P = 0.049; DFS, P G 0.001; DDFS, P = 0.001; non-NAC subgroup: OS, P = 0.014; DFS, P G 0.001; DDFS, P G 0.001). We conclude that prognostic stratification of TNBC ST is ultimately important for optimizing the therapeutic management of patients with these rare tumor entities.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Imaging and histologic prognostic factors in triple-negative breast cancer and carcinoma in situ as a prognostic factor
    Sebastian Sebastian, C.
    Garcia Mur, C.
    Cruz Ciria, S.
    Rosero Cuesta, D. S.
    Gros Baneres, B.
    RADIOLOGIA, 2016, 58 (04): : 283 - 293
  • [42] Prognostic value of various immune cells and Immunoscore in triple-negative breast cancer
    Ren, Xinyu
    Song, Yu
    Pang, Junyi
    Chen, Longyun
    Zhou, Liangrui
    Liang, Zhiyong
    Wu, Huanwen
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [43] Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
    Gong, Yue
    Ji, Peng
    Yang, Yun-Song
    Xie, Shao
    Yu, Tian-Jian
    Xiao, Yi
    Jin, Ming-Liang
    Ma, Ding
    Guo, Lin-Wei
    Pei, Yu-Chen
    Chai, Wen-Jun
    Li, Da-Qiang
    Bai, Fan
    Bertucci, Francois
    Hu, Xin
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CELL METABOLISM, 2021, 33 (01) : 51 - +
  • [44] The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
    Weng, Lijuan
    Zhou, Jianliang
    Guo, Shenchao
    Xu, Nong
    Ma, Ruishuang
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [45] Overexpression of Lox in triple-negative breast cancer
    Leo, Cornelia
    Cotic, Christine
    Pomp, Victoria
    Fink, Daniel
    Varga, Zsuzsanna
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2018, 34 : 98 - 102
  • [46] Role of Platinums in Triple-Negative Breast Cancer
    Lynce, Filipa
    Nunes, Raquel
    CURRENT ONCOLOGY REPORTS, 2021, 23 (05)
  • [47] Male occult triple-negative breast cancer
    Alsayed, Basma
    Abdulla, Hussain Adnan
    Alaskar, Hadi
    Dhaif, Ali
    BMJ CASE REPORTS, 2019, 12 (04)
  • [48] Drivers and suppressors of triple-negative breast cancer
    Wu, Wanfu
    Warner, Margaret
    Wang, Li
    He, Wei-Wei
    Zhao, Ruipeng
    Guan, Xiaoxiang
    Botero, Cindy
    Huang, Bo
    Ion, Charlotte
    Coombes, Charles
    Gustafsson, Jan-Ake
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (33)
  • [49] Biological Subtypes of Triple-Negative Breast Cancer
    Hubalek, Michael
    Czech, Theresa
    Mueller, Hannes
    BREAST CARE, 2017, 12 (01) : 8 - 14
  • [50] Therapeutic Strategies for Triple-Negative Breast Cancer
    Tan, Antoinette R.
    Swain, Sandra M.
    CANCER JOURNAL, 2008, 14 (06) : 343 - 351